An Update of Nucleic Acids Aptamers Theranostic Integration with CRISPR/Cas Technology

Mina Roueinfar; Hayley N Templeton; Julietta A Sheng; Ka Lok Hong

doi:10.3390/molecules27031114

An Update of Nucleic Acids Aptamers Theranostic Integration with CRISPR/Cas Technology

Molecules. 2022 Feb 7;27(3):1114. doi: 10.3390/molecules27031114.

Authors

Mina Roueinfar^{1

2}, Hayley N Templeton¹, Julietta A Sheng¹, Ka Lok Hong^{2

3}

Affiliations

¹ Department of Biomedical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
² Department of Pharmaceutical Sciences, Nesbitt School of Pharmacy, Wilkes University, 84 W. South Street, Wilkes-Barre, PA 18766, USA.
³ Department of Pharmaceutical Sciences, School of Pharmacy, Notre Dame of Maryland University, 4701 North Charles Street, Baltimore, MD 21210, USA.

Abstract

The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system is best known for its role in genomic editing. It has also demonstrated great potential in nucleic acid biosensing. However, the specificity limitation in CRISPR/Cas has created a hurdle for its advancement. More recently, nucleic acid aptamers known for their high affinity and specificity properties for their targets have been integrated into CRISPR/Cas systems. This review article gives a brief overview of the aptamer and CRISPR/Cas technology and provides an updated summary and discussion on how the two distinctive nucleic acid technologies are being integrated into modern diagnostic and therapeutic applications.

Keywords: CRISPR; aptamer; biosensing; molecular recognition elements (MRE); theranostic.

Publication types

Review

MeSH terms

Aptamers, Nucleotide / therapeutic use*
Biosensing Techniques / methods*
CRISPR-Cas Systems*
Gene Editing*
Humans
Precision Medicine*

Substances

Aptamers, Nucleotide